These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 32338556)
21. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705 [TBL] [Abstract][Full Text] [Related]
22. The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Østergaard SD; Foldager L; Mors O; Bech P; Correll CU Acta Psychiatr Scand; 2018 Nov; 138(5):420-431. PubMed ID: 30168131 [TBL] [Abstract][Full Text] [Related]
23. A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients. Huang M; Yu L; Pan F; Lu S; Hu S; Hu J; Chen J; Jin P; Qi H; Xu Y Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():122-130. PubMed ID: 29097257 [TBL] [Abstract][Full Text] [Related]
24. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Meltzer HY; Cucchiaro J; Silva R; Ogasa M; Phillips D; Xu J; Kalali AH; Schweizer E; Pikalov A; Loebel A Am J Psychiatry; 2011 Sep; 168(9):957-67. PubMed ID: 21676992 [TBL] [Abstract][Full Text] [Related]
25. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749 [TBL] [Abstract][Full Text] [Related]
26. Dimensions of schizophrenia and their time course of response to a second generation antipsychotic olanzapine-A clinical study. Birur B; Thirthalli J; Janakiramaiah N; Shelton RC; Gangadhar BN Asian J Psychiatr; 2016 Dec; 24():17-22. PubMed ID: 27931900 [TBL] [Abstract][Full Text] [Related]
27. Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial. Jena M; Ranjan R; Mishra BR; Mishra A; Nath S; Sahu P; Meher BR; Srinivasan A; Maiti R J Psychiatr Res; 2019 May; 112():1-6. PubMed ID: 30782512 [TBL] [Abstract][Full Text] [Related]
28. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. Leucht S; Zhao J J Psychopharmacol; 2014 Apr; 28(4):387-94. PubMed ID: 24429222 [TBL] [Abstract][Full Text] [Related]
29. Early symptom response to antipsychotic medication as a marker of subsequent symptom change: an eighteen-month follow-up study of recent episode schizophrenia. Levine SZ; Leucht S Schizophr Res; 2012 Nov; 141(2-3):168-72. PubMed ID: 22995933 [TBL] [Abstract][Full Text] [Related]
30. Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia: Combined Analysis of 4 RCTs. Kumagai F; Suzuki T; Fleischhacker WW; Yasui-Furukori N; Mimura M; Uchida H J Clin Psychiatry; 2018 Dec; 80(1):. PubMed ID: 30549487 [TBL] [Abstract][Full Text] [Related]
31. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Kane JM; Yang R; Youakim JM Schizophr Res; 2012 Mar; 135(1-3):116-22. PubMed ID: 22178084 [TBL] [Abstract][Full Text] [Related]
32. The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine. Rasmussen SA; Rosebush PI; Anglin RE; Mazurek MF Psychiatry Res; 2016 Jul; 241():72-7. PubMed ID: 27156027 [TBL] [Abstract][Full Text] [Related]
33. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985 [TBL] [Abstract][Full Text] [Related]
34. Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. Stentebjerg-Olesen M; Ganocy SJ; Findling RL; Chang K; DelBello MP; Kane JM; Tohen M; Jeppesen P; Correll CU Eur Child Adolesc Psychiatry; 2015 Dec; 24(12):1485-96. PubMed ID: 26032132 [TBL] [Abstract][Full Text] [Related]
35. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. Lambert M; Holzbach R; Moritz S; Postel N; Krausz M; Naber D Int Clin Psychopharmacol; 2003 Sep; 18(5):251-60. PubMed ID: 12920385 [TBL] [Abstract][Full Text] [Related]